FAME™ Investigator, Dr. Andrew Antoszyk, to Review New Efficacy and Safety Data of ILUVIEN® at the 2011 ARVO Annual Meeting
Company to Hold Conference Call to Discuss First Quarter, 2011 Financial Results and Review New Study Data
ATLANTA, April 26, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that Andrew Antoszyk, M.D. will present new 36 months efficacy and safety data of ILUVIEN® for the treatment of diabetic macular edema at the 2011 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Fort Lauderdale, Florida on Tuesday, May 3, 2011. The presentation will be at 9:15 a.m. in Grand H of the Greater Fort Lauderdale/Broward County Convention Center. Dr. Antoszyk is a practicing retina specialist at Charlotte Eye, Ear, Nose and Throat Associates in Charlotte, North Carolina.
Alimera expects to issue a press release summarizing the new data following the presentation and to file a current report on Form 8-K, which will include Dr. Antoszyk's slides.
Alimera will release its first quarter 2011 financial results after the market closes on May 5, 2011. An investor conference call will follow on the same day at 4:30 P.M. ET.
On the earnings call, management will discuss such financial results and review the new data scheduled to be presented by Dr. Antoszyk.
The conference call will be hosted by Dan Myers, President and Chief Executive Officer, Rick Eiswirth, Chief Operating Officer and Chief Financial Officer, and Ken Green Ph.D., Chief Scientific Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of Alimera's corporate website at .
A replay of the conference call will be available beginning May 5, 2011 at 7:30 P.M. ET and ending on May 19, 2011 by dialing (800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international), Conference ID Number: 62334484. A replay of the webcast will be available on the corporate website for two weeks, through May 19, 2011.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN® is an investigational drug for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. A New Drug Application for ILUVIEN® is currently under review by the U.S. Food and Drug Administration. The FDA, in a December 2010 Complete Response Letter, requested further information including the month 36 data from the FAME™ Study.
CONTACT: ICR, LLC for Alimera Sciences John Mills 310-954-1105 John.Mills@icrinc.com
